Europe's PRAC takes look at lansoprazole

25 February 2014 - Deborah Wilkes

Archived

The European Union's Pharmacovigilance Risk Assessment Committee (PRAC) has asked Takeda to provide additional data on the proton-pump inhibitor lansoprazole.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: